CytomX Therapeutics to Present at the Jefferies Global Healthcare Conference

Rhea-AI Summary

CytomX Therapeutics (NASDAQ: CTMX), a company specializing in masked, conditionally activated biologics, has announced its participation in the upcoming Jefferies Global Healthcare Conference. CEO and Chairman Sean McCarthy will engage in a fireside chat on June 5, 2025, at 2:35 p.m. ET. The presentation will be accessible via live webcast on the company's website at www.cytomx.com under the Events and Presentations section. The company's management team will also be available for one-on-one meetings with registered conference attendees.

SOUTH SAN FRANCISCO, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 5, 2025, at 2:35 p.m. ET.

A live webcast of the presentation will be available on the Events and Presentations page of CytomX’s website at www.cytomx.com. In addition, management will be available for one-on-one meetings with investors who are registered to attend the conference.

About CytomX Therapeutics, Inc.
CytomX is a clinical-stage, oncology-focused biopharmaceutical company focused on developing novel conditionally activated, masked biologics designed to be localized to the tumor microenvironment. By pioneering a novel pipeline of localized biologics, powered by its PROBODY^® therapeutic platform, CytomX’s vision is to create safer, more effective therapies for the treatment of cancer. CytomX’s robust and differentiated pipeline comprises therapeutic candidates across multiple treatment modalities including antibody-drug conjugates (ADCs), T-cell engagers, and immune modulators such as cytokines. CytomX’s clinical-stage pipeline includes CX-2051 and CX-801. CX-2051 is a masked, conditionally activated ADC directed toward epithelial cell adhesion molecule (EpCAM), armed with a topoisomerase-1 inhibitor payload. CX-2051 has potential applicability across multiple EpCAM-expressing epithelial cancers, including CRC, and was discovered in collaboration with ImmunoGen. CX-801 is a masked interferon alpha-2b PROBODY^® cytokine with broad potential applicability in traditionally immuno-oncology sensitive as well as insensitive (cold) tumors. CytomX has established strategic collaborations with multiple leaders in oncology, including Amgen, Astellas, Bristol Myers Squibb, Regeneron and Moderna. For more information about CytomX and how it is working to make conditionally activated treatments the new standard-of-care in the fight against cancer, visit www.cytomx.com and follow us on LinkedIn and X (formerly Twitter).

Company Contact:
Chris Ogden
SVP, Chief Financial Officer
cogden@cytomx.com

Investor Contact:
Precision AQ (formerly Stern Investor Relations)
Stephanie Ascher
stephanie.ascher@precisionaq.com

Media Contact:
Redhouse Communications
Teri Dahlman
teri@redhousecomms.com

FAQ

When is CytomX Therapeutics (CTMX) presenting at the Jefferies Global Healthcare Conference 2025?

CytomX Therapeutics will present at the Jefferies Global Healthcare Conference on Thursday, June 5, 2025, at 2:35 p.m. ET.

Who will represent CytomX Therapeutics (CTMX) at the Jefferies Healthcare Conference?

Sean McCarthy, D.Phil., who serves as the chief executive officer and chairman of CytomX Therapeutics, will represent the company in a fireside chat.

How can investors watch CytomX Therapeutics' (CTMX) presentation at the Jefferies conference?

Investors can watch the live webcast of the presentation on CytomX's website (www.cytomx.com) under the Events and Presentations page.

Will CytomX Therapeutics (CTMX) management be available for individual investor meetings?

Yes, CytomX's management will be available for one-on-one meetings with investors who are registered to attend the conference.